| Prior Art, Obviousness, and the America Invents Act in 2012 TOC |
|
|
| Chapter 1: Section 102, the MPEP and the CAFC--When Is a "Patent" a "Patent," When Is a Clinical Trial an "Experimental Use," and Other Things That Keep You Awake at Night |
Darryl M. Woo ~ Fenwick & West LLP
|
|
| Chapter 2: Obviousness in the USPTO After KSR v. Teleflex |
Carl B. Wischhusen ~ Cozen O'Connor
|
|
| Chapter 3: First-Inventor-to-File, FAQs, and 18 Month Implementation Timeline |
|
|
| Chapter 4: The Leahy-Smith America Invents Act |
Robert A. Armitage ~ Senior Vice President and General Counsel, Eli Lilly and Company
|
|
| Chapter 5: 35 USC 102(f) and 102(g) and the 103(c) Exception and Treatment Under the America Invents Act |
Benjamin C. Hsing ~ Kaye Scholer LLP
Aaron Bernstein ~ Lead Intellectual Property Counsel, Motorola Solutions, Inc.
|
|
| Chapter 6: KSR, Obviousness and the Federal Circuit in 2011 |
Rebecca Goldman Rudich ~ Vedder Price P.C.
|
|
| Chapter 7: 35 U.S.C. Section 102(e) Now and Forever (i.e., New Section 102(d)): Benefit/Priority Effects Under 35 USC Sections 119, 120, 121 and 365 |
Robert J. Spar ~ Patent Prosecution and Practice Specialist, Director (Ret.) OPLA, USPTO,
|
|
| Chapter 8: Flowcharts for 35 U.S.C. Section 102(e) Dates: Apply to All Applications and Patents, Whenever Filed |
Robert J. Spar ~ Patent Prosecution and Practice Specialist, Director (Ret.) OPLA, USPTO,
|
|
| Chapter 9: Index to Prior Art, Obviousness, and the America Invents Act in 2012 |
|
|